

Case Report of Primary Urethral Cancer of Prostate

Ahmet Erhan*, Umit Demirci¹ and Berk Kilinc²

*Department of Urology, Başkent University School of Medicine, Alanya Practice and Research Center, Antalya, Turkey

¹Department of Urology, Ege University, Karabuk, Turkey

²Department of Urology, Istanbul Medipol University, Istanbul, Turkey

Correspondence to Author:

Department of Urology, Başkent University School of Medicine, Alanya Practice and Research Center, Antalya, Turkey

Email: ahmeterhan@hotmail.com

Received Date: Oct 11, 2020

Accepted Date: Oct 14, 2020

Published Date: Nov 16, 2020

Abstract:

Prostatic {adenocarcinoma|adenocarcinoma|glandular cancer|glandular carcinoma} is common and regularly a deadly kind for men. whereas it'd be diagnosed through Digital body part Examination (DRE) by the 50s, the gold commonplace diagnosing methodology for this illness is achieved through the pathological examination of the samples obtained through biopsy. The results of the prostate diagnostic assay, i.e. pathological diagnosing, will be sorted into four: benign prostate dysplasia, adenocarcinoma, endocrine gland Intraepithelial pathologic process (PIN) and Atypical tiny Acinar Proliferation (ASAP). Urothelial cancer diagnosing is a smaller amount typically and is usually among urothelial cancer within the bladder or endocrine gland epithelial duct as primary focus.

INTRODUCTION

Prostate cancer is common and oft a deadly kind for men. whereas it would be diagnosed through Digital body part Examination (DRE) by the 50s, the gold normal identification technique for this sickness is achieved through the pathological examination of the samples obtained through biopsy. The results of the prostate diagnostic assay, i.e. pathological identification, are often sorted into four: benign prostate dysplasia, carcinoma, prostate Intraepithelial pathological process (PIN) and Atypical little Acinar Proliferation (ASAP). Urothelial malignant neoplastic disease identification is a smaller amount typically and is usually amid urothelial malignant neoplastic disease in the bladder or prostate epithelial duct as primary focus. However, although seldom, primary urothelial malignant neoplastic disease will be rumored. This paper presents a case of urothelial malignant neoplastic disease detected through prostate diagnostic assay, beside the relevant literature.

CASE PRESENTATION

A 73-year-old man admitted to the polyclinic with low tract symptoms. His physical examination resulted with a +1 DRE score and his prostate was found to be adenomatous. The reproductive organ examination turned out to be traditional. His routine screenings exhibited a blood creatinine price and diagnosis price inside traditional ranges, whereas his humour prostate specific antigen level was forty eight.9 ng/ml. No pathology was detected by urinary system prenatal diagnosis and the prostate volume was found to be forty eight cc. twelve quadrant prostate diagnostic assay was performed due to the high level of prostate specific antigen level and four quadrants were found to possess intraductal urothelial malignant neoplastic disease. The density of the neoplasm, detected to be positive in 2 right quadrants a pair of|and a couple of|and a pair of| left quadrants,

was found to be 5-15% altogether quadrants. Abdominal distinction pictorial representation was created and therefore the patient was steered cystoprostatectomy. As he refused the steered treatment, he was given goserelin acetate depot and bicalutamide medication. once he came back for management

3 months later, his prostate specific antigen level was found to be fourteen.4 ng/ml. The patient, clinically alleviated by the administered alpha-blocker, was planned to continue the current treatment as he did not go with the steered treatment and failed to adhere to the follow-up advices totally.

DISCUSSION

Prostate cancer is that the second most frequent variety of cancer seen in males with 899,000 new cases every year (14% of all cancer cases in males) [1,2]. glandular cancer would be diagnosed through Digital body part Examination (DRE) by the 50s. Currently, clinical localized prostate cancer is diagnosed through the histopathological assessment of the samples obtained through prostate needle diagnostic assay [3]. Prostate diagnostic assay would 1st[at the start] be performed in DRE steering through transperineal approach throughout the 30s once prostate diagnostic assay was first outlined, and soon through transrectal approach that was outlined by Astraldi [4].

Transrectal Ultrasound target-hunting (TRUS) diagnostic assay performed in the 80s was initial consistently outlined by Hodge et al. [5]. In its early days of definition, this diagnostic assay would be performed with half dozen quadrants, whereas it is presently performed with 8-13 quadrants [6,7]. Now, random TRUS target-hunting diagnostic assay is that the golden commonplace for the pathological designation of prostate [8]. the topic during this study was performed 12-quadrant diagnostic assay.

Indicators for prostate diagnostic assay were high level of body fluid Prostate Specific substance (PSA) and/or suspicion of glandular cancer arising from the DRE. In this case, whereas the outcomes of the DRE were found traditional, the body fluid protein level was found higher than the traditional range; thus the patient was planned for playing diagnostic assay.

The results of the prostate needle diagnostic assay, i.e. pathological designation, may be sorted into four: Benign Prostate dysplasia (BPH), glandular cancer, endocrine gland Intraepithelial pathologic process (PIN) and Atypical tiny Acinar Proliferation (ASAP). whereas the pathological assessment of the cases reveals glandular cancer with a rate of 20-67%, the remainder may be according to be non-cancerous lesions [9]. On the different hand, there isn't comfortable knowledge on urothelial carcinomas diagnosed by prostate needle diagnostic assay. Moreover, a reliable staging system doesn't exist for endocrine gland urothelial carcinomas [10]. Due to the anatomical closeness, urothelial cancer of bladder will invade prostate. In case of suspicion concerning designation {adenocarcinoma|glandular cancer|glandular cancer|carcinoma} or primary endocrine gland urothelial carcinoma in the pathological preparation analyzed when TRUS diagnostic assay, precise discrimination between the 2 entities is vital for creating prognosis and treatment approach. Treatment for glandular cancer is mostly restricted to medical secretion treatment or ablation, primary mode of treatment for urothelial cancer is cystoprostatectomy and therapy [11,12].

While high-stage urothelial cancer and glandular cancer have similar pathological characteristics, there square measure specific distinctive characteristics between them. Major criteria for pathological designation of the cancerous tissue in the prostate diagnostic assay samples square measure infiltrative organ growth pattern, inexistence of basal cells and nuclear atypia. protein is the oldest

and most frequent immunohistochemical marker went to outline prostate-derived cancers [13]. protein and prostate-specific acid enzyme square measure historically used for verification. they will be negative with a rate of nineteen and twenty seventh in cases of prostate-derived however poorly differentiated carcinomas [14,15]. 2 markers are well-tried to be helpful for the designation of prostate glandular cancer: positive diagnostic tissue marker Alpha-Methyl-Acyl-Coenzyme A Racemase (AMACR) for prostate cancer; and p63 that is employed within the designation of prostate adenocarcinoma and doesn't stain the basal membrane within the atypical glands [16-18]. Cytokeratin (CK) seven, CK20 and High-Molecular-Weight Cytokeratin (HMWCK) have been analyzed as potential urothelial markers [19]. Whereas p63 is expressed by most of the urothelial carcinomas, it's negative in most of the prostate adenocarcinomas. p63 could be a reliable marker for urothelial differentiation and it may be used on with different markers in case of issue in morphological differentiation between high-stage urothelial bladder cancer and poorly differentiated prostate glandular cancer [20]. In our case, pathological preparations were stained with hematoxylin-fluorescent dye and urothelial cancer was detected among the benign prostate tissues beneath 40X magnification Figure 1-2).

Prognosis of finest urothelial cancer depends on the prostate invasion degree. No reliable grading system has been developed nevertheless. Non-invasive endocrine gland transmutation cell cancer will with success be treated with conservative agents (TUR +/- BCG), whereas invasive endocrine gland transmutation cell cancer ought to be treated sharply with cystoprostatectomy [10]. In comparison to their acinar forms, such tumors exhibit a hormone-resistant and aggressive biological behavior, and a poor prognosis. Early designation and radical surgery square measure the distinctive approaches that increase the life expectancy [21]. However, in 2003, Morikawa et al. achieved a positive response in an exceedingly case with medical treatment while not surgical intervention, and the pic showing urothelial cancer filing endocrine gland duct (hematoxylin-eosin, original magnification $\times 100$).

PSA level for the topic in question cut to undetectable levels in a pair of months [22]. In our case, the patient was suggested surgery, that he rejected. Medication (goserelin acetate depot and bicalutamide tablet) was administered for the malignity, and a partial response was achieved.

In conclusion, whereas primary urothelial cancer of prostate is rare, just in case of detection, existence of a synchronous urothelial tumour ought to be investigated. Whereas the primary treatment approach is cystoprostatectomy, anti-androgen treatment also can be administered.

REFERENCES

- Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. *CA Cancer J Clin*. 2011; 61: 69-90.
- Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. *Int J Cancer*. 2010; 127: 2893-2917.
- Humphrey PA. Diagnosis of adenocarcinoma in prostate needle biopsy tissue. *PubMed J Clin Pathol*. 2007; 60: 35-42.
- Astraldi A. Diagnosis of cancer of the prostate: biopsy by rectal route. *urolog Cutaneous Rev*. 1937; 41-42.
- Hodge KK, McNeal JE, Stamey TA. Ultrasound guided transrectal core biopsies of the palpably abnormal prostate. *J urol*. 1989; 142: 66-70.
- Eskew LA, Bare RL, McCullough DL. Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate. *J Urol*. 1997; 157: 199-202.
- Babaian RJ, Toi A, Kamoi K, Troncso P, Sweet J, Evans R. A comparative analysis of sextant and an extended 11-core multisite directed biopsy strategy. *J Urol*. 2000; 163: 152-157.
- Norberg M, Egevad L, Holmberg L, Sparén P, Norlén BJ, Busch C. The sextant protocol for ultrasound-guided core biopsies of the prostate underestimates the presence of cancer. *Urology*. 1997; 50: 562-566.
- Raja J, Ramachandran N, Munneke G, Patel U. Current status of transrectal ultrasound-guided prostate biopsy in the diagnosis of prostate cancer. *Clin Radiol*. 2006; 61: 142-153.
- Bassi PF, Falabella R, Sacco E, Raccioppi M. [Transitional cell carcinoma of the prostate]. *Urologia*. 2007; 74: 15-21.
- Liedberg F, Chebil G, Månsson W. Urothelial carcinoma in the prostatic urethra and prostate: current controversies. *Expert Rev Anticancer Ther*. 2007; 7: 383-390.
- Prabhu V, Lee T, McClintock TR, Lepor H. Short-, Intermediate-, and Long-term Quality of Life Outcomes Following Radical Prostatectomy for Clinically Localized Prostate Cancer. *Rev Urol*. 2013; 15: 161-177.
- Epstein JI. PSA and PAP as immunohistochemical markers in prostate cancer. *Urol Clin North Am*. 1993; 20: 757-770.
- Varma M, Jasani B. Diagnostic utility of immunohistochemistry in morphologically difficult prostate cancer: review of current literature. *Histopathology*. 2005; 47: 1-16.
- Varma M, Morgan M, Jasani B, Tamboli P, Amin MB. Polyclonal anti-PSA is more sensitive but less specific than monoclonal anti-PSA: Implications for diagnostic prostatic pathology. *Am J Clin Pathol*. 2002; 118: 202-207.
- Varma M, Berney DM, Jasani B, Rhodes A. Technical variations in prostatic immunohistochemistry: need for standardisation and stringent quality assurance in PSA and PSAP immunostaining. *J Clin Pathol*. 2004; 57: 687-690.
- Jiang Z, Woda BA, Rock KL, Xu Y, Savas L, Khan A. P504S: a new molecular marker for the detection of prostate carcinoma. *Am J Surg Pathol*. 2001; 25: 1397-1404.
- Zhou M, Shah R, Shen R, Rubin MA. Basal cell cocktail (34betaE12 + p63) improves the detection of prostate basal cells. *Am J Surg Pathol*. 2003; 27: 365-371.
- Bassily NH, Vallorosi CJ, Akdas G, Montie JE, Rubin MA. Coordinate expression of cytokeratins 7 and 20 in prostate adenocarcinoma and bladder urothelial carcinoma. *Am J Clin Pathol*. 2000; 113: 383-388.
- Ud Din N, Qureshi A, Mansoor S. Utility of p63 immunohistochemical stain in differentiating urothelial carcinomas from adenocarcinomas of prostate. *Indian J Pathol Microbiol*. 2011; 54: 59-62.

- Queipo Zaragozá JA, Budía Alba A, Pérez Ebrí M, Vera Donoso CD, Vera Sempere F, Jiménez Cruz JF . [Primary transitional carcinoma of the prostatic ductus]. *Actas Urol Esp.* 2000; 24: 406-412.
- Morikawa H, Cho M, Takada S, Fujimoto K, Uemura H, Ozono S. [A case of primary transitional cell carcinoma of the prostate]. *Hinyokika Kyo.* 2003; 49: 357-360.

